This document discusses the use of animal models in pharmaceutical research and their limitations. It describes how animal doses are converted to human equivalent doses using allometric scaling based on body surface area. The document also discusses alternative approaches like computer-based modelling and physiologically-based pharmacokinetic/pharmacodynamic modelling to predict human responses based on data from animal and other preclinical studies in order to reduce risks in early human trials. Several companies that have implemented such modelling approaches are also mentioned.